GlassScriptPhysician profile
Amanda N Douglas
NPI 1386122869
$2,693.16
in general payments reported to CMS, 2019-2025
19 companies · $696 in 2025
The $696 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $283 · 2023: $528 · 2024: $394 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.09 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $309.51 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $298.87 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $246.35 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $227.97 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $177.43 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $135.36 | 2023-2024 | Quviviq |
| Stryker Corporation | $84.70 | 2025 | Neptune |
| Lundbeck LLC | $81.84 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $79.09 | 2021 | |
| Neurocrine Biosciences, INC. | $67.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $54.90 | 2024-2025 | Spravato |
| Novo Nordisk INC | $44.99 | 2022 | |
| Alkermes, INC. | $39.40 | 2025 | Lybalvi |
| Exact Sciences Corporation | $38.94 | 2025 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $24.14 | 2025 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $18.86 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.14 | 2024 | Qelbree |
| Lilly USA, LLC | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.